Drug intelligence / Profile preview

PeriNesta

Development stage: Unknown
Lead developer: Mithra Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**PeriNesta** was Mithra's investigational fixed-dose oral hormonal treatment for women in perimenopause who experienced hot flushes and other vasomotor symptoms while still requiring contraception. The proposed formulation comprised estetrol, a native fetal estrogen produced synthetically for pharmaceutical use, drospirenone, and an unspecified vitamin component. Estetrol provides estrogen-receptor agonism, while drospirenone provides progestogenic activity with antimineralocorticoid and antiandrogenic properties. Mithra discontinued the PeriNesta research program in 2021 before the planned safety study in women around 50 years of age was conducted.

Other names: PeriNesta

Targets

AR (Adrenergic receptors)PR (Progesterone receptor)MR (Mineralocorticoid receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on PeriNesta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeriNesta.

Explore the full profile